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was assumed when generic alternatives became available. RESULTS: The Spanish
population with arterial hypertension over 35 years treated with combinations of
ARBII and CCB with or without DIU was estimated at 990,000 patients in 2010,
expecting to rise to 1.17 million patients in 2013. Total treatment costs for hyper-
tension treatment over the next 3 years were estimated at €1.638 million before the
introduction of SevikarHCT® and at €1.649 million after introduction.
CONCLUSIONS:Although the introduction of SevikarHCT® adds incremental costs
for the Spanish NHS, a decrease in the overall economic burden with or without the
introduction of SevikarHCT® was observed from 2010. These budget savings can be
explained by the effect in price drop caused by the availability of generics.
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OBJECTIVES: To examine evidence on efficacy and safety of oral drugs for pulmo-
nary arterial hypertension (PAH). Analyze their utilization and their cost. To pro-
pose a treatment protocol based on efficacy, safety and efficiency. Calculate the
estimated budget impact after its implementation. METHODS: A search was con-
ducted in MEDLINE, EMBASE and Cochrane Database. Systematic reviews and
meta-analysis of bosentan, ambrisentan, sildenafil or tadalafil in PAH (functional
class II/III) were included. Their utilization was analyzed retrospectively in patients
with primary or associated with connective tissue diseases pulmonary hyperten-
sion that started treatment during 2008 to 2010. The annual cost per patient for
each alternative was calculated (standard dosage). A treatment protocol was de-
veloped, based on efficacy, safety, and efficiency. The incremental cost for each
drug, and the potential savings if all patients start their treatment with the most
cost-effective were calculated. RESULTS: No evidence was found to support the
superiority of any treatment over another, in terms of efficacy and/or safety. Sev-
enteen patients started treatment during the study period (47% bosentan, 41.2%
sildenafil, 11.8% ambrisentan). Estimated annual cost per patient: 30,987.07,
26,861.93, 7,807.74 and 6,865.65 €, for bosentan, ambrisentan, sildenafil and tada-
lafil, respectively. In absence of significant differences in efficacy or safety, the
treatment protocol was based on efficiency (sildenafil tadalafil ambrisentan
bosentan). Incremental cost (compared to sildenafil): 24,121.42, 19,996.28 and
€942.09 for bosentan, ambrisentan and tadalafil, respectively. Estimated potential
savings with implementation of protocol: 77,654.64 €/ year. CONCLUSIONS: No
evidence supports the superiority of any treatment over another, so they could be
considered equivalent therapeutic alternatives. Bosentan is most widely used drug
in naïve patients. The cost associated with bosentan/ambrisentan is markedly
greater to sildenafil/tadalafil. Establishing a protocol that prioritizes sildenafil/
tadalafil use would help to more efficient management of resources.
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OBJECTIVES: To ascertain the cost-utility of patient self-management (PSM) com-
pared to standard monitoring among long-term oral anticoagulation therapy pa-
tients in Austria. METHODS: A Markov model was used to combine international
effectiveness data and local cost and mortality data in a life-long simulation (closed
cohort with a mean baseline age of 67 years). Costs were calculated using informa-
tion on healthcare contacts from healthcare professionals and associated tariffs.
Costs for standard monitoring were based on monthly visits to primary/outpatient
settings and determination of PTZ levels. PSM costs included costs of the hand-
held device, materials, training and regular healthcare check-ups. Costs associated
with complications (thrombotic and haemorrhagic events) in primary-care, acute
care and rehabilitation settings were also considered, since complications occur at
different rates between monitoring strategies. Sensitivity analyses were
performed. RESULTS: PSM was associated with 15.9 life years or 10.7 QALYs com-
pared to 14.6 life years or 9.4 QALYs with standard monitoring. Costs per patient for
the entire period were €7,873 for PSM, €8,170 for monitoring by GPs, €8,354 for
monitoring by community-based consultants and € 8,810 for monitoring at a hos-
pital out-patient clinic. PSM was the dominant strategy for both the cost per life-
year gained and cost per QALY analysis. Although PSM led to higher initial costs
(between €908 and €916 per patient in the first year), follow-up costs were lower
(between €228 and €235 per patient per year thereafter) due to lower frequency of
health care visits. Standard monitoring was associated with monitoring costs of
between €273 and €391 per patient per year. CONCLUSIONS: Encouraging suitable
patients to self-manage leads to better health outcomes and lower costs. In Austria,
initial costs are compensated by lower complication rates and associated costs and
lower monitoring expenses. Cost-savings to the health sector could be accrued as
soon as 3 years after patients switch strategies.
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OBJECTIVES: PLATO was a multi centered, double blind, randomized study that
included 18,624 ACS patients from 43 countries, comparing ticagrelor  aspirin
versus clopidogrel aspirin. The PLATO demonstrated that ticagrelor was superior
on the primary composite endpoint: myocardial infarction, stroke, cardiovascular
death (HR 0.84, 95% CI: 0.77 to 0.92) without an increase in major bleedings com-
pared to clopidogrel, and whether the strategy of choice was invasive or conserva-
tive. The aim of this analysis is to estimate direct health care costs from a Spanish
health care perspective (excluding drug costs because ticagrelor price has not yet
been established). METHODS: Resource utilization was pre specified in the PLATO
trial and included hospitalization bed days, investigations, interventions and blood
products. Direct health care costs per patient at 12 months were estimated by
multiplying the resource use with Spanish unit costs derived from the Spanish
database e-salud, the GRDs of the Ministry of Health, published literature, and the
CMBD 2008. RESULTS: Ticagrelor resulted in numerically fewer bed days (mean
difference per patient 0.21, 95% CI -0.16 to 0.59), PCIs (mean difference per patient
0.01, 95% CI -0.01 to 0.03) and CABGs (mean difference per patient 0.01, 95% CI: 0.00
to 0.01). Ticagrelor is associated with €341 reduction per patient (95% CI: 31 to 652)
in healthcare costs at 12 months compared to clopidogrel. The reduction in health-
care costs was mainly due to fewer hospital days and cardiovascular interventions
in the ticagrelor group. The reduction in cost increased over the 12-month treat-
ment period consistent with the rate of clinical events over time in the PLATO
study. CONCLUSIONS: Treatment with ticagrelor is associated with cost savings in
patients with ACS at 12 months compared with clopidogrel (excluding drug costs)
from a Spanish health care perspective. However, the total cost savings will depend
on drug price, data not available yet.
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OBJECTIVES: To assess the clinical and economic burden of major bleeding in
abdominal surgery patients. METHODS: A retrospective study (January 1, 2005 to
December 31, 2007) was conducted using a medical claims database. Patients in-
cluded in the study were admitted to the hospital with abdominal surgery as their
primary procedure. Patients’ demographic, clinical and discharge statuses were
compared using Chi-square testing and standardized differences. Risk-adjusted
health care visits and costs were estimated using the General Linear Model (GLM).
Potential risk factors for venous thromboembolism (VTE) events were selected
using the Cox Proportional Hazard Regression Model. RESULTS: In patients identi-
fied with abdominal surgery (n49,355), 773 (1.57%) suffered major bleeding in the
6-month follow-up period. Compared with patients who did not suffer major bleed-
ing, patients who did were more likely to be older, have higher Charlson Comor-
bidity Index (CCI) scores and have other comorbid conditions such as cancer. The
percentage of patients who had baseline emergency room (ER) visits was also
higher in the major bleeding group. After risk-adjustment for pre-specified covari-
ates, inpatient ($21,573 vs. $10,954), outpatient ($12,891 vs. $7,852) and pharmacy
costs ($2,025 vs. $1,901) were higher for patients who suffered major bleeding. In
addition, patients with major bleeding events had higher readmission rates (0.11%
vs. 0.03%) during the follow-up period. CONCLUSIONS: Since the health care costs
of patients with major bleeding events were significantly higher than those of
patients without, it is important for individual hospitals to improve major bleeding
prophylaxis therapy.
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OBJECTIVES: To estimate clinical outcomes, health care utilization and cost bur-
den of patients who suffered a transient ischemic attack (TIA) during the 180 days
after a diagnosis of non-valvular atrial fibrillation (NVAF) and compare it with
patients who did not. METHODS: Based on 2005-2007 US insurance claim files,
patients aged 65 years and older who have had two or more primary diagnoses of
NVAF, occurring within 30 days of one another, were selected. The 180 days fol-
low-up event rates, health care facility use and costs for patients with and without
a TIA were compared. Risk adjustment was performed using the propensity score
matching (PSM) method with the ProbChoice™ algorithm. RESULTS: A total of
18,575 patients were identified with NVAF, of which 163 (0.88%) suffered a TIA
during the 180 days after the NVAF diagnosis. Patients were not significantly dif-
ferent in terms of gender, region, and baseline comorbid conditions. After PSM
risk-adjustment for pre-specified covariates, outpatient emergency room (ER) vis-
its (85.89% vs. 48.47% p0.0001), cardiovascular-related length of stay (6.59 days vs.
5.57 days, p0.0001) and ischemic stroke events (89.57 vs. 8 /100 person years,
p0.0001) were higher for patients who suffered a TIA compared to those who did
not. Although risk-adjusted outpatient office visit, international normalized ratio
(INR) testing, Coumadin outpatient visit, drug and other costs did not differ signif-
icantly between the two groups, patients who suffered a TIA had significantly
higher inpatient ($21,740 vs. $22,663, p0.0001) and total ($31,675 vs. $18,045,
p0.0001) expenditures. CONCLUSIONS: After adjusting for patient clinical and
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